ArticleIranian biomedical journal2026
Integrative Analysis of IGFL2‑AS1 and BRCA1 Expression in Esophageal Cancer: An Experimental and Bioinformatics‑Based Study.
Article in Iranian biomedical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal cancer (EC) is a leading cause of cancer-related death worldwide. The long non-coding RNA IGFL2-AS1 is implicated in malignancies, but its role in EC remains unclear. This study evaluated the expression of IGFL2-AS1 and BRCA1 in EC. Methods: Sixteen paired EC and adjacent non-tumorous tissues were collected. The expression levels of IGFL2‑AS1 and BRCA1 were quantified using RT‑qPCR, and BRCA1 protein levels were determined using Western blotting. GEPIA, STRING, and g:Profiler were used for bioinformatic analyses. Receiver-operating characteristic (ROC) curves and correlation tests were performed for statistical evaluation. Results: Both IGFL2-AS1 and BRCA1 were significantly downregulated in EC tissues compared to adjacent normal controls (p < 0.05). A positive correlation was observed between their expression levels. ROC analysis indicated diagnostic potential for both genes (AUC>0.75), with BRCA1 showing superior accuracy. Western blotting confirmed decreased BRCA1 protein levels in tumor samples. Interestingly, GEPIA data suggested an upregulation of both genes in EC. Functional enrichment analysis linked BRCA1-associated genes to ephrin receptor signaling and axon guidance pathways. Conclusion: Concurrent downregulation of IGFL2‑AS1 and BRCA1 at transcript and protein levels was observed in EC tissues, with a positive correlation between their expression levels. ROC curve analysis suggested their potential as candidate biomarkers. However, these findings are preliminary and require further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.